anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to the technical field of daily chemical products and particularly relates to essential oil nanoparticles and a preparation method thereof as well as application of the essential oil nanoparticles to preparation of a mosquito-repelling product. Plant essential oil is used as a mosquito-repelling agent, and all the plant essential oils have synergistic interaction and mutual promotion effects, so that the mosquito-repelling effect is good. Each type of the essential oil is covered with mesoporous silicon dioxide, so that the essential oil can be more stable and has a slow releasing effect. The nanoparticles are added into the mosquito-repelling product so that the adding amount of the essential oil in mosquito-repelling emulsion is reduced and the acting time also is prolonged. According to the mosquito-repelling emulsion provided by the invention, the essential oil, vegetable oil and purslane herb extract can also have anti-allergy and anti-inflammation, and itch-reliving and swelling-eliminating effects, and the irritation on skins is reduced, so that the mosquito-repelling emulsion has better safety and more efficient mosquito-repelling effect. An experiment shows that under a proper proportion, the effective mosquito-repelling time of the mosquito-repelling emulsion provided by the invention can reach 14.1h; and after 18h, the effective repelling rate can still reach 87.3%.
BACKGROUND: The aim of the study was to analyze the Canadian Cardiovascular Society (CCS) guidelines for routine postoperative troponin testing after elective total hip arthroplasty (THA) to reduce the mortality rate resulting from myocardial injury. The purpose of this study was to assess the prognostic relevance of implementing these guidelines to minimize cardiac events in patients undergoing elective THA.
METHODS: Patients who underwent THA surgery in 2020 were included in the study. The inclusion criteria were elective THA patients aged ≥45 years, while emergency, revision, and simultaneous bilateral THA surgeries were excluded. The patients were categorized into 4 groups based on the CCS guidelines.
RESULTS: The study included 669 patients who had an average age of 67 years. There were 43 patients (6.4%), who experienced a rise in troponin levels ≥30 ng/L and developed myocardial injury after noncardiac surgery. Among these patients, 8 developed cardiac complications, and one experienced a serious cardiac event that resulted in death. Notably, there was a significant increase in the length of hospital stay for patients who received the postoperative screening protocol.
CONCLUSIONS: The implementation of the CCS guidelines for routine postoperative troponin testing in elective THA surgery did not significantly decrease the rate of cardiac events or mortality.
PURPOSE: Lactobacillus johnsonii HY7042 is provided to suppress the proliferation of Gardnerella vaginalis by producing hydrogen peroxide(H2O2), to ensure acid resistance and adhesion to vagina cells, and to treat vaginitis. CONSTITUTION: Lactobacillus johnsonii HY7042(deposit number: KCTC12033BP) suppresses the proliferation of pathogenic bacteria causing vaginitis. The strain ensures acid resistance and adhesion to epithelial cells. The proliferation of the pathogenic bacteria is suppressed by suppressing the inflammation of vagina cells after oral administration. The strain has an excellent hydrogen peroxide generation property. The pathogenic bacteria are Gardnerella vaginalis. A pharmaceutical composition for preventing and treating vaginitis contains the strain as an active ingredient. Fermented milk contains the strain as the active ingredient. A functional beverage contains the strain as the active ingredient. Health functional food contains the strain as the active ingredient. [Reference numerals] (AA) Number of pathogenic bacteria(g); (BB) Normal; (CC) Pathogenic bacteria administration; (DD) Pathogenic bacteria administration + HY7042 oral administration; (EE) Pathogenic bacteria administration + HY7042 direct administration
Tumor biological behavior is the fundamental cause of heterogeneous prognosis. The features found on medical images are also reflections of the tumor biological behavior. However, the limitations in spatial and intensity resolution of the naked eye are two inevitable shortcomings of image interpretation by naked eyes, resulting in subjective and limited analyses of images. Computer aided image analyses such as radiomic analysis and machine learning methods are emerging as promising image interpretation methods. The natural advantage of the unlimited spatial and intensity resolution of computers can overcome the shortcomings of visual inspection with the naked eye. Moreover, the massive computing power of computer is also far greater than that of humans. This study will focus on the application of computer aided analysis in predicting treatment response and prognosis in lung cancer.
The effects and mechanisms of cardiac arrhythmias are still incompletely understood and an important subject of cardiovascular research. A major difficulty for investigating arrhythmias is the lack of appropriate human models. Here, we present a protocol for a translational simulation of different types of arrhythmias using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and electric cell culture pacing. The protocol comprises the handling of ventricular and atrial hiPSC-CM before and during in vitro arrhythmia simulation and possible arrhythmia simulation protocols mimicking clinical arrhythmias like atrial fibrillation. Isolated or confluent hiPSC-CM can be used for the simulation. In vitro arrhythmia simulation did not impair cell viability of hiPSC-CM and could reproduce arrhythmia associated phenotypes of patients. The use of hiPSC-CM enables patient-specific studies of arrhythmias, genetic interventions, or drug-screening. Thus, the in vitro arrhythmia simulation protocol may offer a versatile tool for translational studies on the mechanisms and treatment options of cardiac arrhythmias.
OBJECTIVE: Maintenance of long-term arteriovenous access is important in long-term care for patients with end-stage renal disease. Arteriovenous access is associated in the long term with the development of fistula aneurysms (FAs). This study aims to evaluate the outcomes of staged FA treatment in dialysis access arteriovenous fistulae (AVF).
METHODS: A retrospective review of all patients over a 12-year period with primary autogenous AVF was undertaken at a single center. Patients undergoing elective open aneurysm repair were identified and were categorized into three groups: single FA repair (single, control group) and staged and unstaged repair of two FAs (staged and unstaged). A staged repair was a procedure in which the initial intent was to treat both aneurysms in the AVF and in which the most symptomatic aneurysm was treated first. When the incision from the first surgery had healed, the second symptomatic aneurysm in the AVF was treated. An unstaged repair was a procedure in which the initial intent was to repair both symptomatic aneurysms simultaneously. All patients had a fistulogram before the FA repair. Thirty-day outcomes, cannulation failure, line placement, reintervention, and functional dialysis (continuous hemodialysis for 3 consecutive months) were examined.
RESULTS: Five hundred twenty-seven patients presented with FA that met requirements for open intervention; 44% underwent single FA repair, whereas the remaining 34% and 22% underwent staged and unstaged repair of two FAs, respectively. The majority of patients were diabetic and Hispanic. Ninety-one percent of the patients required percutaneous interventions of the outflow tract (37%) and the central veins (54%). Thirty-day major adverse cardiovascular events were equivalent across all modalities. Thirty-day morbidity and early thrombosis (<18 days) were significantly higher in the unstaged group (4.3%) compared with the two other groups (1.3% and 2.1%, single and staged, respectively), which led to an increased need for a short-term tunneled catheter (8.9%) compared with the two other groups (3.4% and 4.4%, single and staged, respectively), Unstaged repair resulted in an increased incidence of secondary procedures (5.0%) compared with the two other groups (2.6% and 3.1%, single and staged, respectively). Functional dialysis at 5 years was equivalent in the single and staged groups but was significantly decreased in the unstaged group.
CONCLUSIONS: Open interventions are successful therapeutic modalities for FAs, but unstaged rather than staged repair of two concurrent FAs results in a higher early thrombosis, an increased secondary intervention rate, and a need for a short-term tunneled central line. Staged and single FA repairs have equivalent results. In the setting of two symptomatic FAs, staged repair is recommended.
For diuretic prepns. 2-(2-methyl-4-chloro- phenylimino-imidazoline or its similarly active acid adduct salts are formulated with non toxic liq. or solid excipients and/or suitable additive. The principal active cpd. is combined with an alpha-antagonist (as Yohimbine) or with a selective opposite antagonist (astnaloxone). - These prepns. are specially useful in the treatment of olednas caused by heart liver, kidney ailments, of glaucomas, of traumatic cerebral oedemas due to tumours or caused post operatively or of menopausal hot flushes
To create a 3D model of part of a cardiovascular system, two 2D images taken of different orientations of the cardiovascular system may be combined. The 2D images originate from video streams taken at different points in time, which comprise frames showing a beating heart, and thus a moving cardiovascular system. Because of this movement, not just any random set of two 2D images may result in useable 3D model. To select a proper set of two 2D images, a method is provided wherein said selection is based on cardiac cycle data. The cardiac cycle data may comprise heart activity data as a function of time and timing data on cycle events. These cycle events may be repetitive, as the same events occur with every heartbeat. The selected frames are preferably selected at, or approximately at, similar events.
Trecator® (ethionamide tablets, USP) is used in the treatment of tuberculosis. The chemical name for ethionamide is 2-ethylthioisonicotinamide with the following structural formula:

C8H10N2S M.W. 166.24 

Ethionamide is a yellow crystalline, nonhygroscopic compound with a faint to moderate sulfide odor and a melting point of 162°C. It is practically insoluble in water and ether, but soluble in methanol and ethanol. It has a partition coefficient (octanol/water) Log P value of 0.3699. Trecator tablets contain 250 mg of ethionamide. The inactive ingredients present are croscarmellose sodium, FD&C Yellow #6, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, povidone, silicon dioxide, talc, and titanium dioxide.
BACKGROUND/AIM: Aggressive breast cancer (BC) cells show high expression of Rho GTPase activating protein 29 (ARHGAP29), a negative regulator of RhoA. In breast cancer cells in which mesenchymal transformation was induced, ARHGAP29 was the only one of 32 GTPase-activating enzymes whose expression increased significantly. Therefore, we investigated whether there is a correlation between expression of ARHGAP29 and tumor progression in BC. Since tamoxifen-resistant BC cells exhibit increased mesenchymal properties and invasiveness, we additionally investigated the relationship between ARHGAP29 and increased invasion rate in tamoxifen resistance. The question arises as to whether ARHGAP29 is a suitable prognostic marker for the progression of BC.
MATERIALS AND METHODS: Tissue microarrays were used to investigate expression of ARHGAP29 in BC and adjacent normal breast tissues. Knockdown experiments using siRNA were performed to investigate the influence of ARHGAP29 and the possible downstream actors RhoC and pAKT1 on invasive growth of tamoxifen-resistant BC spheroids in vitro.
RESULTS: Expression of ARHGAP29 was frequently increased in BC tissues compared to adjacent normal breast tissues. In addition, there was evidence of a correlation between high ARHGAP29 expression and advanced clinical tumor stage. Tamoxifen-resistant BC cells show a significantly higher expression of ARHGAP29 compared to their parental wild-type cells. After knockdown of ARHGAP29 in tamoxifen-resistant BC cells, expression of RhoC was significantly reduced. Further, expression of pAKT1 decreased significantly. Invasive growth of three-dimensional tamoxifen-resistant BC spheroids was reduced after knockdown of ARHGAP29. This could be partially reversed by AKT1 activator SC79.
CONCLUSION: Expression of ARHGAP29 correlates with the clinical tumor parameters of BC patients. In addition, ARHGAP29 is involved in increased invasiveness of tamoxifen-resistant BC cells. ARHGAP29 alone or in combination with its downstream partners RhoC and pAKT1 could be suitable prognostic markers for BC progression.
The invention belongs to the technical field of biological medicines, and particularly relates to a bovine-derived A-type pasteurella multocida inactivated vaccine, and a preparation method and application thereof. The inactivated vaccine prepared by the invention meets the safety requirement of the inactivated vaccine. Establishes a sensitive and specific indirect ELISA method for measuring serum antibodies. The prepared inactivated vaccine is used for immunizing mice and rabbits, can generate a serum antibody with higher titer and longer duration, and the generated antibody can resist the attack of the A-type Pm and simultaneously shows partial protection effect on the attack of the B-type Pm. The inactivated vaccine can be used for immunizing both cows and calves to obtain antibodies with high titer and long duration, and the duration is at least 6 months. Meanwhile, the level of the cow-derived antibody of the born calf is high and is maintained for at least more than 2 months.
Staff Performing ECG (SPE) Group--When the baby is 2-4 weeks of age, research staff will contact the family to schedule a home visit. The QTScreen test will be done by a research assistant.
1. Technical Result Widening of the spectrum of the preparation activity and increase in efficiency of treatment.          2. Essence A biological preparation in a tablet form comprises a mixture of lyophilization concentrates of polyvalent phage (Bactericum polivalentum) bacteria causing a dysentery (Shigellae flexneri, Shigellae sonnei, Shigellae disentericum newcassel) and yeasts Sakharomyces cerevisiae Hansen together with a pharmaceutically acceptable carrier.          3. Field of Application Medicine, therapy.
Ultrasound guided femoral 3 in 1 block using insulated stimulating needle 22 Gauge (G). Ropivacaine 0.375% as per ideal body weight.
This is a prospective, randomized, 2-arm, multicenter study to compare the safety and efficiency of T-DM1 + Afatinib versus T-DM1 in HER2-positive breast cancer patients with active refractory brain metastases. This study will be divided into two phases. The purpose of Phase I is to find out the highest dose of Afatinib that can be given safely with T-DM1. 3 \~ 24 eligible subjects will be enrolled in the study. The purpose of Phase II is to find out whether the dose of Afatinib with T-DM1 determined in Phase I will keep subjects from getting worse for a period of time. The estimated ORR is 17.9 percent in the control group, hypothesis Afatinib can improve the prognosis of subjects, so objective respond rate (ORR) of experimental group is increased by 30 percent, with alpha = 0.025 (unilateral), beta = 0.1. The ratio of the experimental group and control group is 1:1, assuming a 5 percent loss rate. As a result, calculating by PASS 11 software, approximately 106 subjects will be enrolled, with 53 cases in the experimental group, and 53 cases in the control group.
The iv. bolus of UFH (100Units/kg) will be given after obtained femoral vein access and at least 5 minutes prior to the start of the TSP.
Patients with emphysema currently have limited treatment choices. Many patients are treated with steroids and inhaled medications, which often provide little or no benefit. Recently, lung volume reduction surgery has become an accepted therapy for emphysema. Lung volume reduction surgery involves the removal of a diseased portion of the lung, which enables the remaining, healthier portions of the lung to function better. This procedure, although effective, is complicated and risky.

Aeris Therapeutics has developed the Aeris Bronchoscopic Lung Volume Reduction System for treatment of patients with advanced emphysema. The Aeris BLVR System is designed to reduce lung volume without surgery. Patients are treated under anesthesia using a bronchoscope to direct treatment to the most damaged areas of the lung. The treatment is expected to reduce lung volume by shrinking the diseased areas of the lung. The purpose of the current study is to find out whether the Aeris BLVR System is safe in patients with advanced emphysema. The risks associated with the treatment are expected to be similar to those associated with general anesthesia and bronchoscopy.
This disclosure relates to administering, manufacturing, and composing oral formulations to treat and prevent fatty liver disease, liver dysfunction, and hepatic impairment. The treatment and prevention may be one or both liver dysfunction-related primary and secondary diseases. The herbal blend may be made of one or more artichokes, dandelion, milk thistle, alpha-lipoic acid, and turmeric. The enzyme blend may be made of one or more isolated enzymes from amylase, glucoamylase, protease 4.5, protease 6, protease 3, neutral protease, peptidase, papain, alpha-galactosidase, acid maltase, cellulase, pectinase, protease inhibitor 6.0, lipase, lactase, bromelain, cellulase, xylanase, beta-glucanase, invertase, hemicellulose, etc., and any combination thereof. The formulation may be in two compartments, the outer and the inner—the outer compartment has the herbal blend and the internal has the enzyme blend. The inner compartment may be gastric acid resistant.
OBJECTIVE: To assess the evaluation and prevalence of benign hematochezia (BH) vs necrotizing enterocolitis (NEC) in infants with congenital heart disease (CHD) <6 months old admitted to the acute care cardiology unit.
STUDY DESIGN: This was a multicenter retrospective review of patient characteristics and evaluation of all hematochezia events in patients with CHD <6 months admitted to acute care cardiology unit at 3 high-volume tertiary care centers from February 2019 to January 2021. NEC was defined by the Bell staging criteria. Patients with gastrointestinal disorders were excluded.
RESULTS: In total, 180 hematochezia events occurred in 121 patients; 42 patients had more than 1 event. In total, 61% of affected patients had single-ventricle physiology (38% hypoplastic left heart syndrome). Median age and weight at hematochezia were 38 days (IQR 24, 79) and 3.7 kg (IQR 3.2, 4.4). In total, 77% of hematochezia events were BH, and 23% were NEC. There were no surgical interventions for NEC or deaths from NEC. Those with NEC were significantly younger (34 vs 56 days, P < .01) and smaller (3.7 vs 4 kg, P < .01). Single-ventricle physiology was significantly associated with NEC. Initial bloodwork and diagnostic imaging at each center were assessed. There was no significant difference in white blood cell count or C-reactive protein in those with NEC compared with BH. Blood culture results were all negative.
CONCLUSIONS: The majority of infants with CHD with hematochezia have BH over NEC, although single-ventricle and surgical patients remain at greater risk. Infants <45 days are more vulnerable for developing NEC. Bloodwork was noncontributory in the identification of cardiac NEC. Expansion to a prospective study to develop a treatment algorithm is important to avoid overtreatment.
BWell4Life is a 4-week community health promotion program focused on lifestyle change through consumption of a healthy diet and being physically active through weekly educational sessions, setting specific, measurable, attainable, realistic, and timely (S.M.A.R.T.) goals for health behavior modification, and didactic content based on the American Heart Association (AHA) Life's Essential 8 framework. The two diet sessions include an overview of nutrition basics, examples of healthy dietary patterns and cooking methods to increase consumption of plant-based foods and healthy proteins and reduce intakes of red and processed meats, sugary foods, and sugar-sweetened beverages. The two physical activity sessions provide an overview of the physical activity guidelines and include 30-60 minutes of exercise. These sessions also address achieving and maintaining a healthy body weight. Participants will receive a Fitbit for self-monitoring and collecting sleep health and physical activity data.
Backgroundsand Aims. Colorectal cancer (CRC) represents a major global health challenge, necessitating comprehensive investigations into its underlying molecular mechanisms to enhance diagnostic and therapeutic strategies. This study focuses on elucidating the oncogenic role of Membrane-Associated Ring-CH-Type Finger 9 (MARCHF9), a RING-Type E3 ubiquitin transferase, in CRC. We aim to assess MARCHF9's clinical significance, functional impact on CRC progression, and its potential as a prognostic biomarker. Methods. We leveraged data from the Cancer Genome Atlas (TCGA) cohort to evaluate MARCHF9 expression profiles in CRC. In vitro experiments involved siRNA-mediated MARCHF9 knockdown in COAD cell lines (SW480 and LoVo). Cell proliferation and invasion assays were conducted to investigate MARCHF9's functional relevance. Survival analyses were performed to assess its prognostic role. Results. Our analysis revealed significantly elevated MARCHF9 expression in CRC tissues compared to normal colorectal tissues (P < 0.05). High MARCHF9 expression correlated with advanced clinical stages, distant metastases, and the presence of residual tumors in CRC patients. Survival analyses demonstrated that high MARCHF9 expression predicted unfavorable overall and disease-free survival outcomes (P < 0.05). In vitro experiments further supported its oncogenic potential, with MARCHF9 knockdown inhibiting COAD cell proliferation and invasion. Conclusions. This study unveils the oncogenic role of MARCHF9 in CRC, highlighting its clinical relevance as a potential biomarker and therapeutic target. MARCHF9's association with adverse clinicopathological features and its functional impact on cancer cell behavior underscore its significance in CRC progression. Further research is essential to elucidate precise mechanisms by which MARCHF9 enhances tumorigenesis and to explore its therapeutic potential in CRC management.
The present invention relates to a composition for preventing or treating liver diseases comprising an extract of Rosa rugosa Thunb. as an active ingredient. The extract of Rosa rugosa Thunb. is effective in inhibiting phosphorylation of Smad molecules caused by transforming growth factor beta 1 (TGF-1) which is increased when liver cells are damaged, and does not cause toxicity to normal cells. Accordingly, the extract of Rosa rugosa Thunb. can be used as an active ingredient of a medicine for liver diseases or a health functional food for preventing liver diseases.